Oral anti-obesity formulations will be the next growth lever in Danish drugmaker Novo Nordisk's India strategy, following the 2025 launches of its blockbuster diabetes and obesity brands Ozempic and ...

Dublin, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The "International Directory of Generics Companies" directory has been added to ResearchAndMarkets.com's offering. This powerful directory is your connection ...

ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as soon as they’re published. Senators introduced legislation on Thursday that would ...

CORRECTION: An earlier version of this story said Health Canada had approved several generics for semaglutide. They have received several submissions for approval for ...

Teva Pharmaceutical is one of the leading global generic drug manufacturers. By our estimate, roughly 70% of its total revenue is derived from generics and off-patent branded drugs. Generic drugs in ...

Cuban said the high fees the FDA charges to approve generic drugs are a major barrier to manufacturing lower-priced generics in the United States, according to the report. Cuban said Cost Plus Drugs, ...

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...

President Donald Trump has been successful in convincing many of the world’s top drugmakers to commit to manufacturing more of their prescription treatments in the U.S. But what about the onshoring of ...

AFTER AMERICA, China is the world’s largest developer of new medicines. Its companies ran nearly a third of the planet’s clinical trials last year. That is up from just 5% a decade before (see chart 1 ...

As lawmakers eye tougher oversight of pharmacy benefit managers, PBMs seem to be taking their own steps to rein in practices that have invited scrutiny. However, experts remain skeptical and say it ...